Sandra M. Swain

Last updated
Sandra M. Swain
Cropping of Dr. Sandra Swain at ASCO 2013 Annual Meeting.jpg
Swain at ASCO 2013 Annual Meeting in Chicago, IL
Born1954 (age 69–70)
Education University of North Carolina at Chapel Hill (B.A.)
University of Florida (M.D.)
Occupation(s)Oncologist, clinical breast cancer researcher
Years active1980–present

Sandra M. Swain (born 1954) is an American oncologist, breast cancer specialist and clinical translational researcher. [1] She is currently a professor of Medicine at the Georgetown University School of Medicine and the Associate Dean for Research Development at Georgetown University Medical Center (GUMC) and MedStar Health [2] as well as an adjunct professor of Medicine at the F. Edward Hébert School of Medicine of the Uniformed Services University of Health Sciences. [3] She is also a past President of the American Society of Clinical Oncology (ASCO), serving from 2012 through 2013. [1] [2] [3] [4]

Contents

The focus of Sandra's research includes clinical trials and translational research in metastatic and inflammatory breast cancer, adjuvant treatment of breast cancer, the treatments of metastatic HER2+ breast cancer, cardiotoxicity, as well as health care disparities. [1] , [2] , [3] She has authored more than 275 articles on her research in multiple medical journals, including the New England Journal of Medicine (NEJM) and the Journal of Clinical Oncology (JCO). [5] In addition, she has been interviewed in The New York Times [6] and The Wall Street Journal , [7] as well as on NPR's Weekend Edition Sunday [8] and the PBS NewsHour . [9]

Career

After completing her fellowship at the NCI and running clinical trials for two years under Dr. Marc Lippman and alongside Dr. Robert Dickson, Swain founded the breast cancer program at Georgetown University's Lombardi Comprehensive Cancer Center (LCCC) in 1988. [10] This program is now known as the Betty Lou Ourisman Breast Health Center. She returned to the NCI in 1995 and, by 1999, became a Tenured Principal Investigator and the Deputy Chief of the Medicine Branch within the Division of Clinical Sciences, ultimately becoming Chief of the Cancer Therapeutics Branch at the Center for Cancer Research.

In 2007, after a 12-year stint at the NCI, Swain accepted the position of Medical Director at the Washington Cancer Institute (WCI) at the MedStar Washington Hospital Center (MWHC). [1] , [11] At this time, Swain had a growing interest in healthcare inequality and a desire to dedicate her efforts to the underserved African American community in Washington, D.C. During her time as medical director at the WCI, she studied the causes of increased breast cancer mortality observed in African American women. [12] [13] In 2016, after almost a decade at the WCI, Swain was appointed as the Associate Dean for Research Development to pursue research collaborations, business development, and funding opportunities between Georgetown University and industry, medical/scientific associations, governmental agencies, and other entities at all levels. [2]

Over the past 35 years, Swain has held advisory and leadership positions with professional oncology societies and organizations. These include Susan G. Komen for the Cure, the American Society of Clinical Oncology, the Conquer Cancer Foundation, the National Surgical Adjuvant Breast and Bowel Project (NSABP), and the National Accreditation Program for Breast Centers. [14] Swain is a national past-President of the American Society of Clinical Oncology (ASCO) serving from 2012 through 2013. [1] , [2] , [3] , [4] She currently serves as the Secretary for ASCO's Conquer Cancer Foundation. [15]

Bibliography

Related Research Articles

<span class="mw-page-title-main">Trastuzumab</span> Medication

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.

<span class="mw-page-title-main">Anthracycline</span> Class of antibiotics

Anthracyclines are a class of drugs used in cancer chemotherapy that are extracted from Streptomyces bacterium. These compounds are used to treat many cancers, including leukemias, lymphomas, breast, stomach, uterine, ovarian, bladder cancer, and lung cancers. The first anthracycline discovered was daunorubicin, which is produced naturally by Streptomyces peucetius, a species of Actinomycetota. Clinically the most important anthracyclines are doxorubicin, daunorubicin, epirubicin and idarubicin.

<span class="mw-page-title-main">HER2</span> Mammalian protein found in humans

Receptor tyrosine-protein kinase erbB-2 is a protein that normally resides in the membranes of cells and is encoded by the ERBB2 gene. ERBB is abbreviated from erythroblastic oncogene B, a gene originally isolated from the avian genome. The human protein is also frequently referred to as HER2 or CD340.

<span class="mw-page-title-main">Targeted therapy</span> Type of therapy

Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.

<span class="mw-page-title-main">Lapatinib</span> Cancer medication

Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).

<span class="mw-page-title-main">Pertuzumab</span> Pharmaceutical drug

Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.

<span class="mw-page-title-main">José Baselga</span> Spanish oncologist (1959–2021)

Josep Baselga i Torres, known in Spanish as José Baselga, was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein, which is impacted in aggressive breast cancers.

Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification. Triple-negative is sometimes used as a surrogate term for basal-like.

<span class="mw-page-title-main">Afatinib</span> Chemical compound

Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC). It belongs to the tyrosine kinase inhibitor family of medications. It is taken by mouth.

DirectHit is a pharmacodiagnostic test used to determine the tumor sensitivity or resistance to drug regimens recommended for the treatment of breast cancer by the National Comprehensive Cancer Network. It is a noninvasive test performed on small amounts of tissue removed during the original surgery lumpectomy, mastectomy, or core biopsy. DirectHit was developed by CCC Diagnostics Inc., a biotechnology company established by former researchers from Johns Hopkins University. DirectHit was launched on 14 January 2010. Currently, it is the only available test for predicting treatment outcomes for anticancer chemotherapy drugs for breast cancer.

<span class="mw-page-title-main">Trastuzumab emtansine</span> Pharmaceutical drug

Trastuzumab emtansine, sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released and subsequently bind tubulin to cause mitotic arrest and cell death. Trastuzumab binding to HER2 prevents homodimerization or heterodimerization (HER2/HER3) of the receptor, ultimately inhibiting the activation of MAPK and PI3K/AKT cellular signalling pathways. Because the monoclonal antibody targets HER2, and HER2 is only over-expressed in cancer cells, the conjugate delivers the cytotoxic agent DM1 specifically to tumor cells. The conjugate is abbreviated T-DM1.

High-dose chemotherapy and bone marrow transplant (HDC/BMT), also high-dose chemotherapy with autologous bone marrow transplant, was an ineffective treatment regimen for metastatic breast cancer, and later high-risk breast cancer, that was considered promising during the 1980s and 1990s. With an overall idea that more is better, this process involved taking cells from the person's bone marrow to store in a lab, then to give such high doses of chemotherapy drugs that the remaining bone marrow was destroyed, and then to inject the cells taken earlier back into the body as replacement. It was ultimately determined to be no more effective than normal treatment, and to have significantly higher side effects, including treatment-related death.

Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He is director of Yale Cancer Center and president and physician-in-chief of Smilow Cancer Hospital Yale New Haven Health System, effective February 1, 2022. He also is Deputy Dean for Cancer Research at Yale School of Medicine. From 1997 to 2021, he was the Chief of the Breast Oncology Program at Dana–Farber Cancer Institute in Boston, Massachusetts. Beginning in 2013, he held a range of institutional roles at Dana-Farber, including Chief of Clinical Development, the Thompson Chair in Breast Cancer Research and Director of the Dana-Farber/Harvard SPORE in Breast Cancer. He also served as a Professor of Medicine at Harvard Medical School. He was president of the American Society of Clinical Oncology (ASCO) 2022-2023 and became Chair of the Board in mid-June 2023. His career has been focused on breast cancer treatment and research.

<span class="mw-page-title-main">Tucatinib</span> Chemical compound

Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule inhibitor of HER2. It was developed by Array BioPharma and licensed to Cascadian Therapeutics.

<span class="mw-page-title-main">Cancer pharmacogenomics</span>

Cancer pharmacogenomics is the study of how variances in the genome influences an individual’s response to different cancer drug treatments. It is a subset of the broader field of pharmacogenomics, which is the area of study aimed at understanding how genetic variants influence drug efficacy and toxicity.

<span class="mw-page-title-main">Tatiana Prowell</span> American medical oncologist specializing in breast cancer

Tatiana Michelle Prowell is an American medical oncologist specializing in breast cancer. She is an Associate Professor of Oncology at Johns Hopkins School of Medicine and Breast Cancer Scientific Liaison at the U.S. Food & Drug Administration.

Beth Ann Overmoyer is an American physician and oncologist. She is Director of the Inflammatory Breast Cancer Program at the Dana–Farber Cancer Institute.

Nancy Lin is an American oncologist who works at the Dana-Farber Cancer Institute and is an Associate Professor of Medicine at Harvard Medical School. Her research considers new diagnostic strategies and treatment pathways for HER2 positive breast cancer.

Patrick J. Loehrer is an American oncologist who is Indiana University Distinguished Professor, Joseph W. and Jackie J. Cusick Professor in Oncology, Professor of medicine, Indiana University School of Medicine; Director emeritus, Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Xavier Pivot is a French oncologist, university professor, breast cancer specialist and general director of the Strasbourg Cancer Institute.⁣⁣ He is best known for his research on treatments with trastuzumab in HER2-positive breast cancers.

References

  1. 1 2 3 4 5 Breast Cancer Research Foundation (2014-06-23). "Meet Our Researchers: Sandra Swain" . Retrieved October 1, 2016.
  2. 1 2 3 4 5 Healton, Edward B. (April 11, 2016). "Sandra Swain, MD appointed Associate Dean for Research Development" (Press release). Georgetown University. Retrieved October 1, 2016.
  3. 1 2 3 4 Mallet, Karen (June 18, 2012). "Georgetown Lombardi Breast Cancer Expert to Lead ASCO" (Press release). Washington, D.C.: Georgetown University. Retrieved October 1, 2016.
  4. 1 2 American Society of Clinical Oncology (2016-02-09). "Past Presidents" . Retrieved October 1, 2016.
  5. ↑ National Center for Biotechnology Information. "PubMed Author Search" . Retrieved October 2, 2016.
  6. ↑ Andrew Pollack (September 28, 2014). "Roche Breast Cancer Drug Perjeta Appears to Greatly Extend Patients' Lives". The New York Times. Retrieved October 2, 2016.
  7. ↑ Ron Winslow (March 26, 2013). "'Big Data' for Cancer Care: Vast Storehouse of Patient Records Will Let Doctors Search for Effective Treatment". The Wall Street Journal. Retrieved October 2, 2016.
  8. ↑ "Sunday, March 13, 2013". Weekend Edition Sunday. March 31, 2013. NPR. Harnessing Big Data to Combat Cancer.
  9. ↑ Kane, Jason (December 25, 2012). "Commentary: Why Mammograms Are So Crucial". PBS NewsHour. Washington, D.C. Retrieved October 2, 2016.
  10. ↑ Tina Reed (September 9, 2016). "Women Who Mean Business: Sandra Swain". Washington Business Journal . Retrieved October 1, 2016.
  11. ↑ Ronald Piana (June 15, 2012). "New ASCO President Reflect on Value of Mentorship and Addressing Health-care Disparities". The ASCO Post. Retrieved October 1, 2016.
  12. ↑ Banda, Deliya R; Libin, Alexander V; Wang, Hong; Swain, Sandra M (2012). "A Pilot Study of a Culturally Targeted Video Intervention to Increase Participation of African American Patients in Cancer Clinical Trials". The Oncologist. 17 (5): 708–714. doi:10.1634/theoncologist.2012-0454. PMC   3360910 . PMID   22639112.
  13. ↑ Robinson, Brandi N; Newman, Antoinette F; Tefera, Eshetu; Herbolsheimer, Pia; Nunes, Raquel; Gallagher, Chris; Randolph-Jackson, Pamela; Omogbehin, Adedamola; Dilawari, Asma; Pohlmann, Paula R; Mohebtash, Mahsa; Lee, Young; Ottaviano, Yvonne; Mohapatra, Avani; Lynce, Filipa; Brown, Richard; Mete, Mihriye; Swain, Sandra M (2017). "Video intervention increases participation of black breast cancer patients in therapeutic trials". npj Breast Cancer. 3: Article 36. doi:10.1038/s41523-017-0039-1. PMC   5603544 . PMID   28944289.
  14. ↑ MedStar Health Research Institute. "Principal Investigators" . Retrieved October 2, 2016.
  15. ↑ Conquer Cancer Foundation. "Board of Directors" . Retrieved October 3, 2016.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.